Stanley Druckenmiller
NUVB icon

Stanley Druckenmiller’s Nuvation Bio NUVB Stock Holding History

Stanley Druckenmiller’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5M Buy
+4,539,800
New +$25.3M 0.58% 40

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Stanley Druckenmiller's NUVB Position: Q1 2026 in Review

Stanley Druckenmiller opened a new position in Nuvation Bio (NUVB) in Q1 2026: 4,539,800 shares worth $19.5M. The stake represents 0.58% of the portfolio and ranks #40 among its holdings.

231 funds tracked by Wall St. Rank hold NUVB as of Q1 2026.

  • Stanley Druckenmiller held 4,539,800 shares of Nuvation Bio worth $19.5M as of Q1 2026.
  • Nuvation Bio was a new Stanley Druckenmiller position in Q1 2026.
  • Nuvation Bio made up 0.58% of Stanley Druckenmiller's portfolio in Q1 2026, its #40 holding.
  • 231 funds tracked by Wall St. Rank held Nuvation Bio as of Q1 2026.

Based on Duquesne Family Office's 13F filing for Q1 2026, filed 15 May 2026.